Fewer Wuhan Patients For Gilead Remdesivir Study: WHO
China Coronavirus Studies Surge
In a shocking and revealing account, a primary investigator of the front-runner antiviral drug for the coronavirus in China expresses concerns over finding enough patients for the study Wuhan, the outbreak's epicenter.
You may also be interested in...
Public Company Edition: The gene therapy firm’s IPO priced at $18 and ended its first day up 23.3% at $22.20 but fell to $21.50 when stocks recovered on 2 March. Also, RedHill raised $115m for product launches and Movantik purchase, and Avadel raised $65m to compete with Jazz.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Many materials subject to order, APIs needed for OTC as well as Rx drugs, are supplied by companies outside the US, and China accounts for the bulk of them. The order didn't specify countries and products, leaving decisions to FDA.